DRUG AND DEVICE COST-EFFECTIVENESS STUDY PROTOCOLS
Executive Summary
DRUG AND DEVICE COST-EFFECTIVENESS STUDY PROTOCOLS could be designed by FDA, the agency's Office of Device Evaluation Director Susan Alpert said Nov. 15 at a Blue Cross/Blue Shield conference on technology assessment in Arlington, Va. Noting that it has been "rumored that there might be a role for either FDA or another agency within [the Public Health Service] to look at cost effectiveness," Alpert said, "we would see a role for ourselves in designing" cost-effectiveness protocols "because clinical protocols and the evaluations of the products...are in fact within our purview."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth